Share

Related Links

Related Stories

  • New cancer treatment device goes into service
    A treatment system called the Novalis® Tx™ has gone into service, which has the ability to destroy cancerous cells virtually anywhere in the body in a single, 20-minute session, without the need for a single cut of the scalpel.
  • AstraZeneca and Pfizer Join Cancer Research UK’s Stratified Medicine Programme
    CANCER RESEARCH UK will be supported by AstraZeneca and Pfizer in a multimillion pound initiative to examine how genetic tests to improve cancer diagnosis can be best rolled out across the NHS.Cancer Research UK’s pioneering “Stratified Medicine Programme”* will also promote research into new targeted treatments by building a database of genetic information about tumours, treatments and survival rates that will enable researchers to design more effective cancer treatments in future.
  • Together we will beat cancer
    Despite the doom and gloom surrounding the pharmaceutical industry and the many commentaries highlighting inefficiencies of the sectors operating model, 2011 has proven to be a near-record year for approvals of innovative new drugs. These approvals include seven new cancer treatments with two of these (Pfizer’s crizotinib, Xalkori™ and Roche’s vemurafenib, Zelboraf™) made in conjunction with companion genetic tests, reinforcing the notion that the practice of stratified medicine has truly arrived. The forthcoming special issue of Drug Discovery Today on cancer highlights innovative contributions in basic, translational and clinical research made by UK scientists and clinicians in the fight against cancer.
  • Research and development into tumour profiling will lead to improved cancer care
    Six new collaborative research and development projects are set to receive nearly £6 million of government funding in the latest stage of a major five-year initiative to ensure that the UK is a world leader in the development of personalised medicine.
  • Sanofi-aventis to acquire Fovea Pharmaceuticals
    Sanofi-aventis announced recently that it has signed a binding agreement for the acquisition of Fovea Pharmaceuticals SA (‘Fovea‘), a privately held French research and development biopharmaceutical company, focused on ocular diseases.

Top 5 Stories

News

UK cancer patients get robotic radiosurgery treatments

09 February 2010

UK cancer patients to gain access to the latest robotic radiosurgery treatments with the announcement that the Clatterbridge Centre for Oncology has ordered the country’s first Novalis Tx™ radiosurgery platform.

The system, which offers an alternative to surgery for cancer and other abnormalities of the brain and body, will start treating patients when the Centre’s new satellite centre opens in 2011.

Using the radiosurgery platform, doctors at the Centre will be able to offer treatments from stereotactic radiosurgery – a fast treatment designed to eradicate a tumour or lesion in a single session – to longer courses of image-guided radiotherapy, with lower-dose treatment.

Whichever treatment is prescribed, the platform should deliver it quickly. ‘It’s hard for anyone to hold still for long periods of time and movement can compromise treatment accuracy’, says Clatterbridge Senior Research Radiographer Angela Heaton. ‘With the Novalis Tx radiosurgery platform, treatments that would have taken up to an hour or more using other techniques can be completed in just minutes, with no compromise in accuracy.’

‘This technology helps to deliver highly precise treatment to the tumour with minimal side-effects while protecting the surrounding healthy tissue, so we are able to confidently address even the most complex conditions,’ added Mr Mohsen Javadpour, Consultant Neurosurgeon at The Walton Centre, Liverpool, which will be sharing the new system with Clatterbridge.

The platform combines a linear accelerator, which rotates around the patient to deliver treatment beams from any angle, with a set of image guidance and motion management tools that guide patient set-up and positioning and monitor motion during treatment. A high-definition multi-leaf collimator shapes the treatment beam so it matches the shape of the tumour from every angle.

Other radiosurgery devices use circular beams to treat. Because most lesions are irregular in shape, a circular dose does not completely cover the exact shape of the tumour. The platform can also be used to deliver frameless radiosurgery treatments, a more patient-friendly alternative to other systems that require immobilization with a head ring that attaches to the skull.

‘Targeted beams are delivered without an incision from outside the body to destroy tumours or other abnormalities, so patients treated in this way can avoid lengthy recovery periods, and many of the complications often associated with conventional invasive surgery,’ said Dr Brian Haylock, Clinical Director for Radiotherapy at Clatterbridge Centre for Oncology.

 

This article is featured in:
Novel Technologies

 

Comment on this article

You must be registered and logged in to leave a comment about this article.